This accredited learning module explores how to initiate injectable therapy in a patient with type 2 diabetes who remains above their glycaemic target despite taking dual or triple oral therapy. The activity works through 3 in-depth case-studies: a patient with uncomplicated T2D, a patient with ASCVD risk, and a patient with established ASCVD.
Late effects of polio include post-polio syndrome and symptoms such as residual weakness, musculoskeletal imbalance, growth retardation or skeletal deformities in affected limbs, respiratory insufficiency and cold intolerance due to circulatory disturbances. Many patients living with the late effects of polio are unaware that their current presenting symptoms could be related to their initial polio infection. This module aims to educate GPs on the late effects of polio and how to identify and support affected patients.
From 1 October 2021, Australians will require a prescription to legally access e-cigarettes containing nicotine (e-cigarettes), liquid nicotine, and other novel nicotine delivery products, such as heat-not-burn tobacco products. Read about the Therapeutic Goods Administration’s decision about e-cigarettes and what this means for prescribers.
Review practical recommendations from Australian diabetes experts on when and how to use IDegAsp (insulin degludec/insulin aspart) in real-world practice.
This series of podcasts aims to provide general practitioners (GPs) and other healthcare professionals with the latest clinically relevant information and opinions from experts in T2DM about the appropriate management of patients with T2DM in primary care, particularly regarding insulin therapy.
Strong steps in osteoporosis: Learning a step-wise approach to identifying and preventing osteoporotic fracture
This module takes participants though a step-wise model which helps identify patients at risk of osteoporotic fracture, and looks at strategies for prevention and ongoing management.
This education module focuses on a case study of an uncomplicated patient with type 2 diabetes, and the process of intensifying to first injectable therapy. Expert video commentary throughout the module helps step the participant through the decision cycle from the ADA/EASD consensus guidelines for T2D. This module also includes Australian recommendations for patients fasting during Ramadan.
In this education module, the participant will work through a case study of a type 2 diabetes patient with ASCVD risk factors. The case study uses the decision cycle from the ADA/EASD consensus guidelines for T2D, and features expert video commentary. The module also discusses patient-related concerns leading to clinical inertia, including useful management decisions when faced with this issue.